Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

#What Is The Predicted Market Size Of The Extended-Release Drugs Industry By 2029?#_x000D_

The market size for extended-release medication has seen a significant expansion in the past few years. With a compound annual growth rate (CAGR) of 10.3%, the market is projected to increase from $63.11 billion in 2024 to $69.63 billion in 2025. The reasons for this growth during the historic period are improvements in patient compliance, increased prevalence of chronic diseases, enhanced efficiency, patent protection strategies, and biodegradable implants._x000D_

_x000D_

The market size of extended-release drugs is projected to expand considerably in the coming years, forecasted to reach “$111.26 billion by 2029 with a compound annual growth rate (CAGR) of 12.4%. This accelerated growth during the forecast period can be credited to tailored medical treatments, patient-focused drug evolution, an increasing frequency of lifestyle diseases, drug re-application, and worldwide availability of extended-release therapies. Key trends expected to influence the forecast period include pharmaceutical breakthroughs, advancements in drug dispersal systems, progress in nanotechnology, the usage of 3D printing in drug constitution, deployment of artificial intelligence, and persistence on environmental sustainability._x000D_

_x000D_

#Get A Free Sample Of The Report:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=12675&type=smp_x000D_

_x000D_

#Which Factors Are Steering Growth In The Extended-Release Drugs Market?#_x000D_

The extended-release drug market is anticipated to expand due to the rising prevalence of chronic diseases. Chronic diseases, which require ongoing medical care, limit daily activities or both, are ailments that persist over a year. Examples include heart disease, obesity, cancer, and diabetes. Extended-release medication delivery systems are engineered to maintain a steady medication concentration in the body for an extended length of time. It promotes steady therapeutic action and prevents drug level fluctuations that immediate-release medications might cause. For instance, the US-based National Library of Medicine, National Center for Biotechnology Information (NCBI), predicted in January 2023 that by 2050, the population aged 50 years and above suffering from at least one chronic disease will ascend by 99.5%, reaching up to 142.66 million. Ergo, the augmenting prevalence of chronic diseases is fuelling the growth of the extended-release drug market._x000D_

_x000D_

#How Is The Extended-Release Drugs Market Segmented Across Key Categories?#_x000D_

The extended-release drugs market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Sustained Release Drug, Controlled Release Drug_x000D_

2) By Mode: Over-The-Counter, Prescription_x000D_

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores_x000D_

_x000D_

Subsegments:_x000D_

1) By Sustained Release Drug: Matrix Systems, Coating Systems _x000D_

2) By Controlled Release Drug: Osmotic Systems, Microencapsulation Systems, Targeted Delivery Systems _x000D_

_x000D_

#What Key Trends Are Driving Growth In The Extended-Release Drugs Market?#_x000D_

The extended-release drug market is increasingly trending towards product innovation. Major players in the market are creating inventive products to maintain their competitiveness. For example, in July 2022, Zydus Pharmaceuticals (USA) Inc., a manufacturer of generic pharmaceuticals based in the U.S., launched extended-release capsules of Topiramate for epilepsy. The U.S. Food and Drug Administration (USFDA) had previously given Zydus the green light to commercialize these capsules in 25 mg, 50 mg, and 100 mg doses. The enterprise is the first in the nation to get final approval and roll out these Topiramate extended-release capsules. The Topiramate extended-release tablets have been greenlit for use in treating individuals with partial onset or primary generalized tonic-clinic seizure._x000D_

_x000D_

#Which Companies Are Contributing Significantly To The Extended-Release Drugs Market Growth?#_x000D_

Major companies operating in the extended-release drugs market include Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Eastman Chemical Company, Catalent Pharma Solutions Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, Hisamitsu Pharmaceutical Co. Inc., Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Ardena Holding NV, UPM Pharmaceuticals Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Lavipharm Laboratories Inc., Watson Pharmaceuticals Inc. _x000D_

_x000D_

#Access The Complete Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/extended-release-drugs-global-market-report_x000D_

_x000D_

#Which Region Dominates The Extended-Release Drugs Market Today?#_x000D_

North America was the largest region in the extended-release drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the extended-release drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Customize Your Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=12675&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model